Healthcare shares are flat in pre-market. In stocks news, ISIS
) says data from a Phase 2 study of ISIS-APOCIIIRx as a monotherapy
in patients with familial chylomicronemia syndrome, or FCS, reduced
FCS is a rare orphan disease characterized by severely high
triglyceride levels that affects an estimated 3,000 to 5,000
In this study, three patients with FCS treated with
ISIS-APOCIIIRx achieved substantial reductions in triglycerides.
Patients also achieved substantial reductions in apoC-III and
apoCIII-associated very low-density lipoprotein-cholesterol
particles. ISIS is steady at $36.06.
And, Alexion Pharmaceuticals (
) says researchers have presented data from an ongoing
multinational Phase 2 study of asfotase alfa in infants and young
children with hypophosphatasia (
), an inherited, ultra-rare metabolic disorder that in this patient
population leads to progressive damage to multiple vital organs,
destruction and deformity of bones, and death.
The study met its primary endpoint: infants and young children
with HPP treated with asfotase alfa had significant improvement in
skeletal mineralization from baseline as assessed radiographically
after 24 weeks of treatment. ALXN is flat at $113.65.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.